Discovery and validation of urinary biomarkers for prostate cancer

Proteomics - Clinical Applications

Volumn 2, Issue 4, 2008, Pages 556-570

  Theodorescu, Dan ^a,b   Schiffer, Eric ^c   Bauer, Hartwig W ^d   Douwes, Friedrich ^e   Eichhorn, Frank ^f   Polley, Reinhard ^g   Schmidt, Thomas ^f   Schöfer, Wolfgang ^f   Zurbig, Petra ^c   Good, David M ^h   Coon, Joshua J ^h,i   Mischak, Harald ^c  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c MOSAIQUES DIAGNOSTICS GMBH   (Germany)

^d UNIVERSITY OF MUNICH   (Germany)

^e St George Hospital Bad Aibling   (Germany)

^f Urological Office   (Germany)

^g Urological Office   (Germany)

^h UNIVERSITY OF WISCONSIN MADISON   (United States)

ⁱ UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Capillary electrophoresis; Diagnosis; Mass spectrometry; Prostate carcinoma; Urine

Indexed keywords

POLYPEPTIDE; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ADULT; AGE DISTRIBUTION; AGED; AMINO ACID SEQUENCE; ARTICLE; CAPILLARY ELECTROPHORESIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE FLUID; PROTEIN ANALYSIS; SENSITIVITY AND SPECIFICITY; URINALYSIS; VALIDATION PROCESS;

EID: 42449130178     PISSN: 18628346     EISSN: None     Source Type: Journal    
DOI: 10.1002/prca.200780082     Document Type: Article

References (75)

1. Jemal, A., Siegel, R., Ward, E., Murray, T. et al., Cancer statistics, 2006. CA Cancer J. Clin. 2006, 56, 106-130.
2. Stamey, T. A., Yang, N., Hay, A. R., McNeal, J. E. et al., Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N. Engl. J. Med. 1987, 317, 909-916.
3. Presti, J. C., Jr., Prostate cancer: Assessment of risk using digital rectal examination, tumor grade, prostate-specific antigen, and systematic biopsy. Radiol. Clin. North Am. 2000, 38, 49-58.
4. Thompson, I. M., Goodman, P. J., Tangen, C. M., Lucia, M. S. et al., The influence of finasteride on the development of prostate cancer. N. Engl. J. Med. 2003, 349, 215-224.
5. Thompson, I. M., Pauler, D. K., Goodman, P. J., Tangen, C. M. et al., Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N. Engl. J. Med. 2004. 350, 2239-2246.
6. Wang, X., Yu, J., Sreekumar, A., Varambally, S. et al., Auto-antibody signatures in prostate cancer. N. Engl. J. Med. 2005, 353, 1224-1235.
7. Ornstein, D. K., Rayford, W., Fusaro, V. A., Conrads, T. P. et al., Serum proteomic profiling can discriminate prostate cancer from benign prostates in men with total prostate specific antigen levels between 2.5 and 15.0 ng/ml. J. Urol. 2004, 172, 1302-1305.
8. Conrads, T. P., Hood, B. L., Issaq, H. J., Veenstra, T. D., Proteomic patterns as a diagnostic tool for early-stage cancer: A review of its progress to a clinically relevant tool. Mol. Diagn. 2004, 8, 77-85.
9. Gelmann, E. P., Semmes, O. J., Expression of genes and proteins specific for prostate cancer. J. Urol. 2004, 172, S23-S26.
10. Kolch, W., Neususs, C., Pelzing, M., Mischak, H., Capillary electrophoresis-mass spectrometry as a powerful tool in clinical diagnosis and biomarker discovery. Mass Spectrom. Rev. 2005, 24, 959-977.
11. Mueller, J., von Eggeling, F., Driesch, D., Schubert, J. et al., ProteinChip technology reveals distinctive protein expression profiles in the urine of bladder cancer patients. Eur. Urol. 2005, 47, 885-893.
12. Vlahou, A., Schellhammer, P. F., Mendrinos, S., Patel, K. et al., Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. Am. J. Pathol. 2001, 158, 1491-1502.
13. Vlahou, A., Giannopoulos, A., Gregory, B. W., Manousakas, T. et al., Protein profiling in urine for the diagnosis of bladder cancer. Clin. Chem. 2004, 50, 1438-1441.
14. Munro, N. P., Cairns, D. A., Clarke, P., Rogers, M. et al., Urinary biomarker profiling in transitional cell carcinoma. Int. J. Cancer 2006, 119, 2642-2650.
15. Zhang, Y. F., Wu, D. L., Guan, M., Liu, W. W. et al., Tree analysis of mass spectral urine profiles discriminates transitional cell carcinoma of the bladder from noncancer patient. Clin. Biochem. 2004, 37, 772-779.
16. Liu, W., Guan, M., Wu, D., Zhang, Y. et al., Using tree analysis pattern and SELDI-TOF-MS to discriminate transitional cell carcinoma of the bladder cancer from noncancer patients. Eur. Urol. 2005, 47, 456-462.
17. Zerefos, P., Prados, J., Kossida, S., Kalousis, A., Vlahou, A., Sample preparation and bioinformatics in MALDI profiling of urinary proteins. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2007, 853, 20-30.
18. Kaiser, T., Wittke, S., Just, I., Krebs, R. et al., Capillary Electrophoresis coupled to mass spectrometer for automated and robust polypeptide determination in body fluids for clinical use. Electrophoresis 2004, 25, 2044-2055.
19. Theodorescu, D., Wittke, S., Ross, M. M., Walden, M. et al., Discovery and validation of new protein biomarkers for urothelial cancer: A prospective analysis. Lancet Oncol. 2006, 7, 230-240.
20. Schaub, S., Wilkins, J., Weiler, T., Sangster, K. et al.. Urine protein profiling with surface-enhanced laser-desorption/ionization time-of-flight mass spectrometry. Kidney Int. 2004, 65, 323-332.
21. Mischak, H., Julian, B. A., Novak, J., High-resolution proteome/ peptidome analysis of peptides and low-molecular-weight proteins in urine. Proteomics Clin. Appl. 2007, 1, 792-804.
22. Thongboonkerd, V., Recent progress in urinary proteomics. Proteomics Clin. Appl. 2007, 1, 780-791.
23. Chalmers, M. J., Kolch, W., Emmett, M. R., Marshall, A. G., Mischak, H., Identification and analysis of phosphopeptides. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2004, 803, 111-120.
24. Decramer, S., Wittke, S., Mischak, H., Zurbig, P. et al., Predicting the clinical outcome of congenital unilateral ureteropelvic junction obstruction in newborn by urinary proteome analysis. Nat. Med. 2006, 12, 398-400.
25. Weissinger, E. M., Schiffer, E., Hertenstein, B., Ferrara, J. L. et al., Proteomic patterns predict acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood 2007, 109, 5511-5519.
26. Wittke, S., Haubitz, M., Walden, M., Rohde, F. et al., Detection of acute tubulointerstitial rejection by proteomic analysis of urinary samples in renal transplant recipients. Am. J. Transplant. 2005, 5, 2479-2488.
27. Mischak, H., Apweiler, R., Banks, R. E., Conaway, M. et al., Clinical proteomics: A need to define the field and to begin to set adequate standards. Proteomics Clin. Appl. 2007, 1, 148-156.
28. Taylor, C. F., Paton, N. W., Lilley, K. S., Binz, P. A. et al., The minimum information about a proteamics experiment (MIAPE). Nat. Biotechnol. 2007, 25, 887-893.
29. Girasole, C. R., Cookson, M. S., Putzi, M. J., Chang, S. S. et al., Significance of atypical and suspicious small acinar proliferations, and high grade prostatic intraepithelial neoplasia on prostate biopsy: Implications for cancer detection and biopsy strategy. J. Urol. 2006, 175, 929-933.
30. Epstein, J. I., Herawi, M, Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: Implications for patient care. J. Urol. 2006, 175, 820-834.
31. Obiezu, C. V., Shan, S. J., Soosaipillai, A., Luo, L. Y. et al., Human kallikrein 4: Quantitative study in tissues and evidence for its secretion into biological fluids. Clin. Chem. 2005, 51, 1432-1442.
32. Acevedo, B., Perera, Y., Torres, E., Penton, D. et al., Fast and novel purification method to obtain the prostate specific antigen (PSA) from human seminal plasma. Prostate 2006, 66, 1029-1036.
33. Weissinger, E. M., Wittke, S., Kaiser, T. Haller, H. et al., Proteomic patterns established with capillary electrophoresis and mass spectrometry for diagnostic purposes. Kidney Int. 2004, 65, 2426-2434.
34. Theodorescu, D., Fliser, D., Wittke, S., Mischak, H. et al., Pilot study of capillary electrophoresis coupled to mass spectrometry as a tool to define potential prostate cancer biomarkers in urine. Electrophoresis 2005, 26, 2797-2808.
35. DeLeo, J. M., Receiver operating characteristic laboratory (ROCLAB): Software for developing decision strategies that account for uncertainty. Second International Symposium on Uncertainty Modeling and Analysis, College Park, MD, USA, April 25, 1993, pp. 318-325.
36. Benjamini, Y., Hochberg, Y., Controlling the false discovery rate: A practical and powerful approach to multiple testing. J. R. Stat. Soc. B (Methodological) 1995, 57, 125-133.
37. Mukherjee, S., Kashino, S. S., Zhang, Y., Daifalla, N. et al., Cloning of the gene encoding a protective Mycobacterium tuberculosis secreted protein detected in vivo during the initial phases of the infectious process. J. Immunol. 2005, 175, 5298-5305.
38. Weissinger, E. M., Kaiser, T., Meert, N., De Smet, R. et al., Proteomics: A novel tool to unravel the patho-physiology of uraemia. Nephrol. Dial. Transplant. 2004, 19, 3068-3077.
39. Dieterle, F., Muller-Hagedorn, S., Liebich, H. M., Gauglitz, G., Urinary nucleosides as potential tumor markers evaluated by learning vector quantization. Artif. Intell. Med. 2003, 28, 265-279.
40. Brown, M. P., Grundy, W. N., Lin, D., Cristianini, N. et al., Knowledge-based analysis of microarray gene expression data by using support vector machines. Proc. Natl. Acad. Sci. USA 2000, 97, 262-267.
41. Zürbig, P., Renfrow, M. B., Schiffer, E., Novak, J. et al., Biomarker discovery by CE-MS enables sequence analysis via MS/MS with platform-independent separation. Electrophoresis 2006, 27, 2111-2125.
42. Coon, J. J., Shabanowitz, J., Hunt, D. F., Syka, J. E., Electron transfer dissociation of peptide anions. J. Am. Soc. Mass Spectrom. 2005, 16, 880-882.
43. Syka, J. E., Coon, J. J., Schroeder, M. J., Shabanowitz, J., Hunt, D. F., Peptide and protein sequence analysis by electron transfer dissociation mass spectrometry. Proc. Natl. Acad. Sci. USA 2004, 101, 9528-9533.
44. Lilja, H., Structure and function of prostatic- and seminal vesicle-secreted proteins involved in the gelation and liquefaction of human semen. Scand. J. Clin. Lab. Invest. Suppl. 1988, 191, 13-20.
45. Lilja, H., Cell biology of semenogelin. Andrologia 1990, 22, 132-141.
46. Lodding, P., Aus, G., Bergdahl, S., Frosing, R. et al., Characteristics of screening detected prostate cancer in men 50 to 66 years old with 3 to 4 ng/ml. Prostate specific antigen. J. Urol. 1998, 159, 899-903.
47. Punglia, R. S., D'Amico, A. V., Catalona, W. J., Roehl, K. A., Kuntz, K. M., Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. N. Engl. J. Med. 2003, 349, 335-342.
48. Roehl, K. A., Antenor, J. A., Catalona, W. J., Serial biopsy results in prostate cancer screening study. J. Urol. 2002, 167, 2435-2439.
49. Amsellem-Ouazana, D., Younes, P., Conquy, S., Peyromaure, M. et al., Negative prostatic biopsies in patients with a high risk of prostate cancer, is the combination of endorectal MRI and magnetic resonance spectroscopy imaging (MRSI) a useful tool? A preliminary study. Eur. Urol. 2005, 47, 582-586.
50. Anastasiadis, A. G., Lichy, M. P., Nagele, U., Kuczyk, M. A. et al., MRI-guided biopsy of the prostate increases diagnostic performance in men with elevated or increasing PSA levels after previous negative TRUS biopsies. Eur. Urol. 2006, 50, 738-748.
51. Chun, F. K., Karakiewicz, P. I., Briganti, A., Walz, J. et al., A critical appraisal of logistic regression-based nomograms, artificial neural networks, classification and regression-tree models, look-up tables and risk-group stratification models for prostate cancer. BJU Int. 2007, 99, 794-800.
52. Eastham, J. A., May, R., Robertson, J. L., Sartor, O., Kattan, M. W., Development of a nomogram that predicts the probability of a positive prostate biopsy in men with an abnormal digital rectal examination and a prostate-specific antigen between 0 and 4 ng/mL. Urology 1999, 54, 709-713.
53. Veltri, R. W., Miller, M. C., O'dowd, G. J., Partin, A. W., Impact of age on total and complexed prostate-specific antigen cutoffs in a contemporary referral series of men with prostate cancer. Urology 2002, 60, 47-52.
54. Lehrer, S., Roboz, J., Ding, H., Zhao, S. et al., Putative protein markers in the sera of men with prostatic neoplasms. BJU Int. 2003, 92, 223-225.
55. Liu, A. Y., Zhang, H., Sorensen, C. M., Diamond, D. L., Analysis of prostate cancer by proteomics using tissue specimens. J. Urol. 2005, 173, 73-78.
56. Semmes, O. J., Feng, Z., Adam, B. L., Banez, L. L. et al., Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility. Clin. Chem. 2005, 51, 102-112.
57. Malik, G., Ward, M. D., Gupta, S. K., Trosset, M. W. et al., Serum levels of an isoform of apolipoprotein A-II as a potential marker for prostate cancer. Clin. Cancer Res. 2005, 11, 1073-1085.
58. Paul, B., Dhir, R., Landsittel, D., Hitchens, M. R., Getzenberg, R. H., Detection of prostate cancer with a blood-based assay for early prostate cancer antigen. Cancer Res. 2005, 65, 4097-4100.
59. Uetsuki, H., Tsunemori, H., Taoka, R., Haba, R. et al., Expression of a novel biomarker, EPCA, in adenocarcinomas and precancerous lesions in the prostate. J. Urol. 2005, 174, 514-518.
60. Dhir, R., Vietmeier, B., Arlotti, J., Acquafondata, M. et al., Early identification of individuals with prostate cancer in negative biopsies. J. Urol. 2004, 171, 1419-1423.
61. Fernandez, C., Rifai, N., Wenger, A. S., Mickey, D. D., Silverman, L. M., A preliminary study of urinary transferrin as a marker for prostatic cancer. Clin. Chim. Acta 1986, 161, 335-339.
62. Teni, T. R., Sheth, A. R., Kamath, M. R., Sheth, N. A., Serum and urinary prostatic inhibin-like peptide in benign prostatic hyperplasia and carcinoma of prostate. Cancer Lett. 1988, 43, 9-14.
63. Hutchinson, L. M., Chang, E. L., Becker, C. M., Ushiyama, N. et al., Development of a sensitive and specific enzyme-linked immunosorbent assay for thymosin beta15, a urinary biomarker of human prostate cancer. Clin. Biochem. 2005, 38, 558-571.
64. Rogers, C. G., Yan, G., Zha, S., Gonzalgo, M. L. et al., Prostate cancer detection on urinalysis for alpha methylacyl coenzyme a racemase protein. J. Urol. 2004, 172, 1501-1503.
65. Lwaleed, B. A., Francis, J. L., Chisholm, M., Urinary tissue factor levels in patients with bladder and prostate cancer. Eur. J. Surg. Oncol. 2000, 26, 44-49.
66. Stoeber, K., Swinn, R., Prevost, A. T., Clive-Lowe, P. et al., Diagnosis of genito-urinary tract cancer by detection of minichromosome maintenance 5 protein in urine sediments. J. Natl. Cancer Inst. 2002, 94, 1071-1079.
67. Rehman, I., Azzouzi, A. R., Catto, J. W., Allen, S. et al., Proteomic analysis of voided urine after prostatic massage from patients with prostate cancer: A pilot study. Urology 2004, 64, 1238-1243.
68. M'koma, A. E., Blum, D. L., Norris, J. L., Koyama, T. et al., Detection of preneoplastic and neoplastic prostate disease by MADI profiling of urine. Biochem. Biophys. Res. Commun. 2006, 353, 829-834.
69. Blok, L. J., Chang, G. T., Steenbeek-Slotboom, M., van Weerden, W. M. et al., Regulation of expression of Na+,K+ATPase in androgen-dependent and androgen-independent prostate cancer. Br. J. Cancer 1999, 81, 28-36.
70. Sternlicht, M. D., Werb, Z., How matrix metalloproteinases regulate cell behavior. Annu. Rev. Cell Dev. Biol. 2001, 17, 463-516.
71. Brew, K., Dinakarpandian, D., Nagase, H., Tissue inhibitors of metalloproteinases: Evolution, structure and function. Biochim. Biophys. Acta 2000, 1477, 267-283.
72. Hu, R., Wu, R., Deng, J., Lau, D., A small proline-rich protein, spr1: Specific marker for squamous lung carcinoma. Lung Cancer 1998, 20, 25-30.
73. Lau, D., Guo, L., Chan, A., Wu, R., SPR1. An early molecular marker for bronchial carcinogenesis. Methods Mol. Med. 2003, 75, 397-403.
74. Lau, D., Xue, L., Hu, H., Liaw, T. et al., Expression and regulation of a molecular marker, SPR1, in multistep bronchial carcinogenesis. Am. J. Respir. Cell Mol. Biol. 2000, 22, 92-96.
75. DeMuth, J. P., Weaver, D. A., Crawford, E. L., Jackson, C. M., Willey, J. C., Loss of spr1 expression measurable by quantitative RT-PCR in human bronchogenic carcinoma cell lines. Am. J. Respir. Cell Mol. Biol. 1998, 19, 25-29.